Related Experiment Video
Updated: Jun 4, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective
1Brigham and Women's Hospital, Boston, Massachusetts, USA.
Annals of Internal Medicine
|February 12, 1998
Summary
Factor V Leiden mutation increases venous thromboembolism risk but screening utility is uncertain. Further trials are needed to determine optimal anticoagulation strategies for affected individuals.
Area of Science:
- Genetics
- Hematology
- Thrombosis Research
Background:
- Factor V Leiden is a common genetic mutation causing resistance to activated protein C.
- This resistance leads to a hypercoagulable state and increased risk of blood clots.
- The mutation is present in 4-6% of the U.S. population.
Purpose of the Study:
- To review clinical data on factor V Leiden mutation.
- Emphasis on prevalence and risks of thromboembolism.
- Implications for screening and management strategies.
Main Methods:
- MEDLINE search (1993-April 1997) and bibliography review.
- Inclusion of case-control, cohort studies, and original research articles.
- Review of case reports when analytic data were unavailable.
Main Results:
- Factor V Leiden mutation increases venous thromboembolism risk 3-6 fold, especially without transient risk factors.
- Risk is higher with coexisting thrombotic predispositions (e.g., oral contraceptives, deficiencies).
- No increased risk for arterial thrombosis observed; anticoagulation benefit is unknown.
Conclusions:
- Factor V Leiden mutation predisposes to venous thromboembolism.
- Screening utility remains uncertain.
- Management decisions depend on trials evaluating anticoagulation benefits versus risks.
Keywords:
AmericasBiologyBlood Coagulation EffectsBlood ProteinsContraceptionContraceptive Methods--pharmacodynamicsDeveloped CountriesDiseasesEmbolismExaminations And DiagnosesFamily PlanningGeneticsHematological EffectsHemic SystemLiterature ReviewNorth AmericaNorthern AmericaOral Contraceptives, Combined--pharmacodynamicsOral Contraceptives--pharmacodynamicsPhysiologyRisk FactorsScreeningThromboembolismUnited StatesVascular DiseasesMore Related Videos
08:30Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
Published on: August 14, 2017
08:01The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...